Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mass spectrometry identification of biomarker candidates in the prediagnostic plasmas in the Women's Health Initiative cohort. Mass spectrometry identification.

Published byEustacia Quinn Modified over 5 years ago

Similar presentations

Presentation on theme: "Mass spectrometry identification of biomarker candidates in the prediagnostic plasmas in the Women's Health Initiative cohort. Mass spectrometry identification."— Presentation transcript:

1 Mass spectrometry identification of biomarker candidates in the prediagnostic plasmas in the Women's Health Initiative cohort. Mass spectrometry identification of biomarker candidates in the prediagnostic plasmas in the Women's Health Initiative cohort. Schema of three biomarker candidates (AK1, CLIC1, and SOD1) and identification of peptides by mass spectrometry. Gray bars indicate identified peptides. Numbers indicate mass spectra counts for each peptide, and numbers in parentheses indicate mass spectra counts with quantification. The amino acid sequence is based on P for AK1, O for CLIC1, and P for SOD1 in the UniProt Knowledgebase. Ayumu Taguchi et al. Cancer Prev Res 2015;8: ©2015 by American Association for Cancer Research

Download ppt "Mass spectrometry identification of biomarker candidates in the prediagnostic plasmas in the Women's Health Initiative cohort. Mass spectrometry identification."

Similar presentations

Peptide de novo sequencing Peptide de novo sequencing is the analytical process that derives a peptide’s amino acid sequence from its tandem mass spectrum.

Peptide de novo sequencing Peptide de novo sequencing is the analytical process that derives a peptide’s amino acid sequence from its tandem mass spectrum.
Odds ratios for change in PD from earliest mammogram within levels of earliest PD. No evidence for an interaction of earliest PD and change in PD on breast.

Odds ratios for change in PD from earliest mammogram within levels of earliest PD. No evidence for an interaction of earliest PD and change in PD on breast.
KG-501 suppresses NSCLC/IL-1β CM–induced migration of HUVECs by regulating IL-1β–induced CXC chemokine gene expression in NSCLC cells. KG-501 suppresses.

KG-501 suppresses NSCLC/IL-1β CM–induced migration of HUVECs by regulating IL-1β–induced CXC chemokine gene expression in NSCLC cells. KG-501 suppresses.
IL-1β differentially regulates CXCL5 and CXCL8 protein secretion in NHTBE and NSCLC cells. IL-1β differentially regulates CXCL5 and CXCL8 protein secretion.

IL-1β differentially regulates CXCL5 and CXCL8 protein secretion in NHTBE and NSCLC cells. IL-1β differentially regulates CXCL5 and CXCL8 protein secretion.
IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.

IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.
25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.
by Nelson Leung, Samih H. Nasr, and Sanjeev Sethi

by Nelson Leung, Samih H. Nasr, and Sanjeev Sethi
Variability in protein concentration of urine over a 10-d collection from a single healthy volunteer. Variability in protein concentration of urine over.

Variability in protein concentration of urine over a 10-d collection from a single healthy volunteer. Variability in protein concentration of urine over.
Quantification of readthrough peptides in the presence of paromomycin

Quantification of readthrough peptides in the presence of paromomycin
Alignment of H-NS, H-NS2, and StpA amino acid sequences.

Alignment of H-NS, H-NS2, and StpA amino acid sequences.
A, high resolution MS/MS spectrum (lower panel) of 1435

A, high resolution MS/MS spectrum (lower panel) of 1435
Effect of supplementation with SeMet or SY on plasma selenium levels in adult men. Effect of supplementation with SeMet or SY on plasma selenium levels.

Effect of supplementation with SeMet or SY on plasma selenium levels in adult men. Effect of supplementation with SeMet or SY on plasma selenium levels.
Correction of translational start site by identification of N-terminal peptide. Correction of translational start site by identification of N-terminal.

Correction of translational start site by identification of N-terminal peptide. Correction of translational start site by identification of N-terminal.
N-terminal extension of a gene using peptides mapping upstream to an annotated start site. N-terminal extension of a gene using peptides mapping upstream.

N-terminal extension of a gene using peptides mapping upstream to an annotated start site. N-terminal extension of a gene using peptides mapping upstream.
Relative quantification of cis and trans PSP gp10040–42/47–52 variants

Relative quantification of cis and trans PSP gp10040–42/47–52 variants
Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)

Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)
ROC curve for separating advanced stages (advanced BE and EA) versus early stages (BE or BE instability) using total genome-wide LOH [area under the curve.

ROC curve for separating advanced stages (advanced BE and EA) versus early stages (BE or BE instability) using total genome-wide LOH [area under the curve.
Localization of putative cholesterol-binding motifs in the homology model of human glucose transporter 1 (GLUT1) protein. Localization of putative cholesterol-binding.

Localization of putative cholesterol-binding motifs in the homology model of human glucose transporter 1 (GLUT1) protein. Localization of putative cholesterol-binding.
Schematic of AIMS-to-MRM experiment.

Schematic of AIMS-to-MRM experiment.
Clinically significant precounseling cancer distress modifies counseling method's effect on testing uptake. *, statistically significant difference observed.

Clinically significant precounseling cancer distress modifies counseling method's effect on testing uptake. *, statistically significant difference observed.

Similar presentations

Ads by Google